doi: 10.1016/j.leukres.2009.12.018.
Epub 2010 Jan 21.
Centrosome amplification as a possible marker of mitotic disruptions and cellular carcinogenesis in multiple myeloma
Affiliations
- PMID: 20096458
- DOI: 10.1016/j.leukres.2009.12.018
Item in Clipboard
Centrosome amplification as a possible marker of mitotic disruptions and cellular carcinogenesis in multiple myeloma
Leuk Res.
2010 Aug.
Abstract
Centrosome amplification (CA) as a potential marker of mitotic disruptions in multiple myeloma (MM) was investigated in two populations of B-cell lineage: B-cells and plasma cells (PCs). Using immunofluorescent staining, it was shown that CA in B-cells is present in 3.2+/-2.5% in healthy donors versus 9.9+/-7.9% in MM patients (p<0.0001). Based on the calculated threshold value of CA in B-cells, 37% (14/38) of MM patients were positive. There was no significant correlation between CA-positive MM cases (based on PC samples evaluation) and the occurrence of cytogenetic abnormalities in PCs, including del(13)(q14), del(17)(p13), gain(1)(q21) and hyperdiploidy.
Copyright (c) 2010 Elsevier Ltd. All rights reserved.
Similar articles
-
Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark.Cancer Genet Cytogenet. 2007 Apr 15;174(2):89-99. doi: 10.1016/j.cancergencyto.2006.11.015. Cancer Genet Cytogenet. 2007. PMID: 17452249
-
Visualization of numerical centrosomal abnormalities by immunofluorescent staining.Klin Onkol. 2011;24 Suppl:S49-52. Klin Onkol. 2011. PMID: 21923065
-
Chromosome 13q deletion and IgH abnormalities may be both masked by near-tetraploidy in a high proportion of multiple myeloma patients: a combined morphology and I-FISH analysis.Cancer Lett. 2007 Oct 8;255(2):307-14. doi: 10.1016/j.canlet.2007.05.005. Epub 2007 Jun 27. Cancer Lett. 2007. PMID: 17590504
-
Cutaneous involvement in multiple myeloma: a clinicopathologic, immunohistochemical, and cytogenetic study of 8 cases.Arch Dermatol. 2003 Apr;139(4):475-86. doi: 10.1001/archderm.139.4.475. Arch Dermatol. 2003. PMID: 12707095 Review.
-
Centrosome amplification and clonal evolution in multiple myeloma: Short review.Crit Rev Oncol Hematol. 2016 Feb;98:116-21. doi: 10.1016/j.critrevonc.2015.10.019. Epub 2015 Nov 2. Crit Rev Oncol Hematol. 2016. PMID: 26589397 Review.
Cited by
-
Drug Targeting of Genomic Instability in Multiple Myeloma.Front Genet. 2020 Apr 9;11:228. doi: 10.3389/fgene.2020.00228. eCollection 2020. Front Genet. 2020. PMID: 32373151 Free PMC article. Review.
-
Centrosome associated genes pattern for risk sub-stratification in multiple myeloma.J Transl Med. 2016 May 28;14(1):150. doi: 10.1186/s12967-016-0906-9. J Transl Med. 2016. PMID: 27234807 Free PMC article.
-
Low cyclin F expression in hepatocellular carcinoma associates with poor differentiation and unfavorable prognosis.Cancer Sci. 2013 Apr;104(4):508-15. doi: 10.1111/cas.12100. Epub 2013 Feb 17. Cancer Sci. 2013. PMID: 23305207 Free PMC article.
-
Structural and Functional Analyses of the FAM46C/Plk4 Complex.Structure. 2020 Aug 4;28(8):910-921.e4. doi: 10.1016/j.str.2020.04.023. Epub 2020 May 19. Structure. 2020. PMID: 32433990 Free PMC article.
-
Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma.J Transl Med. 2013 Mar 23;11:77. doi: 10.1186/1479-5876-11-77. J Transl Med. 2013. PMID: 23522059 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
